Abstract
9636 Background: Rolapitant is a highly selective competitive long acting NK-1 receptor antagonist that successfully achieved the primary endpoint of complete response (no emesis and no rescue medi...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
